Possible repurposing of other established radiopharmaceuticals to investigate COVID-19–specific pathomechanisms might target the cytokine signaling pathway (e.g., chemokine receptor CXCR4, interleukin IL-6), fibroblast activation protein inhibitors (FAPI), to address postinflammatory fibrosis, or inhibitors of the type 1 angiotensin-II-receptor ATR1 (e.g., KR31173), involved in cellular internalization of SARS-CoV-2 (2). The gene discussed is AGTR1; the disease is COVID-19.